|Title:||Saving money on the PBS: Ranibizumab or Bevacizumab for Neovascular Macular Degeneration?|
|Citation:||Harvey K, Day R, Campbell W, Lipworth W. 2011. Saving money on the PBS: Ranibizumab or Bevacizumab for Neovascular Macular Degeneration? Medical Journal of Australia. 194 (11), 567-568 (Lead editorial)|
|Abstract:||Federal Health Minister Nicola Roxon recently met with an alliance of consumer, industry and other stakeholders to justify the government’s plan to indefinitely delay the listing of seven new medicines on the Pharmaceutical Benefits Scheme (PBS). She argued that, after considering the advice of the Pharmaceutical Benefits Advisory Committee (PBAC), it was the government’s responsibility to decide whether or not to list a new drug, taking into account other priorities across the health portfolio and current fiscal circumstances. 1 Clearly, the cost of the PBS must be sustainable. However, there are other ways of reducing its cost apart from delaying the listing of drugs recommended by PBAC as cost-effective. The treatment of macular degeneration provides an illustrative example.|
|Type of Work:||Article|
|Type of Publication:||Publisher version|
|Appears in Collections:||Research Papers and Publications. Sydney Health Ethics|
|MJA_SavingMoneyonthePBS.pdf||600.17 kB||Adobe PDF|
Items in Sydney eScholarship Repository are protected by copyright, with all rights reserved, unless otherwise indicated.